Trial Profile

A Phase 3 Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Uproleselan (Primary) ; Decitabine
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

16 Jun 2025 According to a Crescent Biopharma media release, GlycoMimetics has been merged with Crescent Biopharma. The combined company will operate under the name Crescent Biopharma.
06 May 2024 According to a GlycoMimetics Inc. media release ,this study did not meet its primary endpoint of overall survival in the intent to treat population.
06 May 2024 Topline results published in GlycoMimetics Inc. the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com